8/30/2013 9:41:43 AM
EWING, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that U.S. Patent number 8,518,437 was issued by the United States Patent and Trademark Office on August 27, 2013. The new patent, “Lipid Carrier Compositions with Enhanced Blood Stability,” covers Celator’s proprietary low-cholesterol liposome compositions utilized in the Company's two clinical stage products, CPX-351 and CPX-1, which are based on the company’s innovative technology platform called CombiPlex. With the Patent Term Adjustment, this patent provides protection until June 2026.
Help employers find you! Check out all the jobs and post your resume.
comments powered by